Key Highlights

  • Bodycote confirmed near-identical possible cash offers from CVC and Veritas Capital valuing the group at roughly £1.56bn
  • Shares jumped 23.1% on the day to close near 923p after the approaches were disclosed
  • CVC has proposed 915p per share and Veritas 914p per share, both including the declared interim dividend
  • H1 2026 Revenue rose 3.3% to £381.2m and adjusted operating profit climbed 10.7% to £61.0m
  • Both bidders must declare a firm intention to bid or walk away by 5pm on 2 September 2026

Two of the buyout industry's larger names are competing for control of one of Britain's quieter industrial champions. On 5 August 2026 Bodycote (LSE:BOY), the Macclesfield-based thermal-processing specialist, confirmed it had received near-identical possible cash offers from CVC and Veritas Capital, valuing the FTSE 250 group at roughly £1.56bn. The board said it would be "minded to recommend unanimously" either proposal, should a firm offer materialise. Shares jumped 23.1% on the day to close near 923p. The clock is now running: under the Takeover Code, both suitors must declare a firm intention to bid or walk away by 5pm on 2 September. What began as private manoeuvring has become a public contest, though not yet a settled deal.

Company and news background

Bodycote is the world's largest provider of heat treatment and specialist thermal-processing services, the unglamorous but critical metallurgical work that hardens, strengthens and coats components for aerospace, defence, automotive, energy, medical and semiconductor customers. It operates a global network of plants and earns its keep on process expertise and proximity to manufacturers rather than on any single product.

The takeover interest did not appear from nowhere. In its 5 August statement, the company disclosed that both bidders had approached the board previously, with Veritas having done so on a number of occasions. CVC Advisers Limited has tabled a proposal worth 915p per share, comprising 907.8p in cash plus the 7.2p Interim Dividend already declared. Veritas Capital Fund IX sits fractionally behind at 914p, made up of 906.8p in cash and the same dividend entitlement. Both proposals remain conditional on confirmatory due diligence, to which access has been granted, and on agreeing definitive documentation. Barclays and Goldman Sachs are advising Bodycote, with Herbert Smith Freehills Kramer on legals and FTI Consulting handling communications.

A note of precision matters here. These are "possible offers" under Rule 2.4 of the Code, not firm offers under Rule 2.7. The gap between the two prices is a single penny, so this is better described as competing approaches than an established auction. Whether it escalates into a genuine bidding war depends on what emerges before the September deadline.

The numbers that matter

Bodycote's interim results, published in late July, help explain why financial buyers are circling. First-half revenue rose 3.3% to £381.2m, or 6.5% on an organic basis. Adjusted operating profit climbed 10.7% to £61.0m, lifting the adjusted Operating Margin by 110 basis points to 16.0%. Adjusted Basic Earnings Per Share advanced 18.3% to 25.2p, and the interim dividend was raised 4.3% to 7.2p. Net Debt excluding leases stood at £135.2m, with free Cash Flow of £14.5m over the half.

Beneath the headline sits a sharpening portfolio. The company now separates its core into Specialist Technologies, which generated £121.2m of revenue at a 26.1% margin with organic growth of 16.7%, and Precision Heat Treatment at £250.8m, a 15.0% margin and 6.4% organic growth. The higher-margin specialist work, spanning surface technologies and hot isostatic pressing, is doing the heavy lifting on both growth and profitability.

The prior year sets the contrast. FY2025 revenue fell 4.0% to £727.1m and adjusted operating profit dropped 11.4% to £114.3m as automotive weakness and a sharp oil and gas decline bit. Management held the full-year dividend at 23.0p and pressed on with its "Optimise" restructuring, which closed eight sites, divested ten French operations for £19m and is targeting at least £15m of run-rate benefits by mid-2027. The 2026 recovery in margins suggests that self-help is beginning to show.

What is driving the story

The Investment case rests on a divergence within Bodycote's end markets. Aerospace and defence, industrial gas turbines, medical and semiconductors are all growing, some briskly, as Supply chains normalise and defence budgets swell across Europe. Against that, automotive Demand remains soft, especially in Europe, and general industrial activity has been subdued. The bull argument is that Bodycote is quietly rotating towards structurally stronger, higher-margin work while the weaker legacy exposure shrinks as a share of the whole.

For private equity, the appeal is straightforward. Bodycote throws off cash, owns a defensible market position that is hard to replicate, and carries modest leverage, leaving ample room to gear up a buyout. The Optimise programme offers a ready-made value-creation plan, and the aerospace and defence cycle provides a credible growth story. A depressed valuation for a UK-listed industrial with global operations completes the picture. That combination has made the London market a fertile hunting ground for overseas capital, and Bodycote fits the template neatly.

What it means for investors

For shareholders, the immediate calculus is about price and certainty. The 23.1% jump to roughly 923p implies an undisturbed price in the region of 750p before the approaches surfaced, putting the premium at around a fifth. That is respectable but hardly a knockout blow for a Business whose margins are recovering and whose specialist arm is compounding at double digits. Some holders may feel that near-matched bids clustered a penny apart look more like a floor than a full valuation.

The bear case is real. Automotive weakness could persist, defence enthusiasm could cool, and a cash offer crystallises value today at the cost of forgoing the upside from a self-help recovery only half delivered. The Balance Sheet is comfortable rather than stretched, which is precisely why a leveraged buyer can pay in cash. On valuation, the offers price Bodycote at a meaningful step up from where it traded, yet against its own history and the quality of the specialist franchise, the multiple is not obviously generous.

Competitively, Bodycote's scale and process know-how remain its moat, and neither bidder is proposing to dismantle that. The risk for public-market investors is losing access to a rare, cash-generative UK industrial just as its turnaround gains traction.

What comes next

The pivotal date is 2 September, when CVC and Veritas must each either firm up or withdraw. Three broad paths follow. One or both could convert to a formal Rule 2.7 offer, at which point the board's willingness to recommend becomes decisive and the near-identical pricing could force a genuine auction. Alternatively, one party may drop out, leaving a single suitor and less pricing tension. Or the approaches could lapse entirely, returning Bodycote to standalone life with its shares likely giving back much of their gain.

The signal to watch is whether either bidder breaks materially above 915p. A widening spread would confirm a contested process; continued near-parity would suggest disciplined buyers unwilling to overpay. Antitrust and foreign-investment clearances are unlikely to be prohibitive for a services business of this kind, so timing rather than regulation should dominate.

Bodycote's board has, in effect, signalled that the right cash price would win its backing. The judgement facing shareholders is whether a low-twenties premium adequately compensates for surrendering a recovering, structurally advantaged industrial. On the evidence so far, this is a serious approach rather than a concluded takeover, and the difference is worth several hundred million pounds.